Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O'Connor OA. Falchi L, et al. Among authors: montanari f. Blood. 2021 Apr 22;137(16):2161-2170. doi: 10.1182/blood.2020009004. Blood. 2021. PMID: 33171487 Free article. Clinical Trial.
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
O'Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone MM, Nandakumar R, Soderquist CR, Park DC, Bhagat G, Cheng B, Risueño A, Menezes D, Shustov AR, Sokol L, Scotto L. O'Connor OA, et al. Among authors: montanari f. Blood. 2019 Oct 24;134(17):1395-1405. doi: 10.1182/blood.2019001285. Blood. 2019. PMID: 31471376 Free article. Clinical Trial.
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.
Scotto L, Kinahan C, Douglass E, Deng C, Safari M, Casadei B, Marchi E, Lue JK, Montanari F, Falchi L, Qiao C, Renu N, Bates SE, Califano A, O'Connor OA. Scotto L, et al. Among authors: montanari f. Mol Cancer Ther. 2021 Aug;20(8):1422-1430. doi: 10.1158/1535-7163.MCT-20-0377. Epub 2021 Jun 9. Mol Cancer Ther. 2021. PMID: 34108263 Free PMC article.
Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers.
Scotto L, Kinahan C, Casadei B, Mangone M, Douglass E, Murty VV, Marchi E, Ma H, George C, Montanari F, Califano A, O'Connor OA. Scotto L, et al. Among authors: montanari f. Genes Chromosomes Cancer. 2020 Nov;59(11):639-651. doi: 10.1002/gcc.22884. Epub 2020 Jul 30. Genes Chromosomes Cancer. 2020. PMID: 32614991 Free PMC article.
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience.
Sawas A, Ma H, Kuruvilla J, Lue JK, Deng C, Marchi E, Montanari F, Cheng B, Savage KJ, Villa D, Crump M, Connors JM, O'Connor OA. Sawas A, et al. Among authors: montanari f. Leuk Lymphoma. 2020 Dec;61(12):3014-3017. doi: 10.1080/10428194.2020.1795161. Epub 2020 Jul 28. Leuk Lymphoma. 2020. PMID: 32720828 Clinical Trial. No abstract available.
123 results